Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren Fiskus

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Leukemia|March 28, 2023
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Christopher P Mill, Warren Fiskus, Kaberi Das, et al.
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Cancer Cell|June 13, 2023
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell LymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Leukemia|March 28, 2023
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Christopher P Mill, Warren Fiskus, Kaberi Das, et al.
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Cancer Cell|June 13, 2023
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell LymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Pageof 10